No registrations found.
ID
Source
Brief title
Health condition
- Children
- Cancer
- Mucositis
- Nutrition
Sponsors and support
Intervention
Outcome measures
Primary outcome
Feeding strategy (tube feeding, tpn) and duration in days
Secondary outcome
- Severity of mucositis measured by plasma citrulline (during regular vena punctures, no extra punctures will be done for study purpose only, the remaining plasma will be used to measure citrulline)
- Number of days of mucositis >grade 1, and the peak severity of mucositis according to the NCI-CTCAE criteria
- Weight, daily
- Number of days with pain and the peak level of pain, daily measured with the VAS/Faces score
- Days of analgesics, and the total amount of analgesics
- The number of infectious complications and number of positive blood cultures
- Length of hospital stay
Background summary
Since there are no data on children with mucositis, and because of the inconsistency in the available literature and clinical practice, we set up this research project to study which strategy is currently used in the clinical practice in pediatric cancer patients with chemotherapy induced mucositis, how many times a switch to parenteral nutrition is inevitable, and what the consequences of feeding strategies are on clinical outcomes. In a multicenter prospective observational study, children (0-18 yrs of age) admitted to the UMCG or AMC, for treatment of B-NHL, or autologous SCT will be included. Feeding strategy (own intake, tube feeding, tpn) and duration in days will be the main outcome.
Study objective
What is the current feeding strategy in pediatric cancer patients suffering from chemotherapy induced mucositis?
Study design
- after chemotherapy course: daily
Intervention
-
Hanzeplein 1
W.J.E. Tissing
Groningen 9713 GZ
The Netherlands
+31 (0)50 3614213
w.j.e.tissing@umcg.nl
Hanzeplein 1
W.J.E. Tissing
Groningen 9713 GZ
The Netherlands
+31 (0)50 3614213
w.j.e.tissing@umcg.nl
Inclusion criteria
Children (0-18 yrs of age) admitted to the University Medical Center Groningen (UMCG) or Academic
Medical Center (AMC) Amsterdam, for treatment of B Non Hodgkin lymphoma (B-NHL), or autologous stem cell transplantation(SCT)
Exclusion criteria
-
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4730 |
| NTR-old | NTR5070 |
| Other | : METc 2014/423 |